Michael Siekman > Goodwin > Boston, United States > Lawyer Profile
Goodwin Offices

100 NORTHERN AVENUE
BOSTON MA 02210
MASSACHUSETTS
United States
- Firm Profile
- Go to...
Michael Siekman

Position
Partner
Career
A partner in Goodwin’s Life Sciences group and Intellectual Property practice, Michael Siekman focuses his practice on intellectual property matters, including patent prosecution, licensing and post-grant proceedings and litigation. Leveraging over 25 years of experience, Michael has built in-depth patent portfolios, particularly advising clients in the biotechnology and pharmaceutical industries.
Michael keeps clients’ business goals in mind as he regularly provides legal counsel in the litigation matters, including Hatch-Waxman matters, and post-grant solutions for biosimilars. He has successfully led matters before the Patent Trial and Appeal Board (PTAB) and the European Patent Office. His transactional practice involves licensing agreements, collaboration agreements, and IP-related aspects of mergers, acquisitions, IPOs and other financings.
Michael has extensive experience with biosimilars and has written and presented often on the topic. One of his biosimilar articles has been cited in three amicus briefs to the Supreme Court in two cases involving the PTAB.
As a parent of a child with Type 1 diabetes, Michael particularly enjoys working with biopharma and device companies in that space.
Education
JD, 1995
Boston University School of Law (concentration in Intellectual Property, with Honors)
BS, Biology, 1990
Bates College
Top Tier Firm Rankings
- Industry focus > Cannabis
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Intellectual property > Patents: licensing
- M&A/corporate and commercial > Private equity buyouts: middle-market (Up to $500m)
- Real estate > Real estate investment trusts (REITs)
- Media, technology and telecoms > Technology transactions
- M&A/corporate and commercial > Venture capital and emerging companies
Firm Rankings
- Finance > Capital markets: equity offerings
- Dispute resolution > E-discovery
- Labor and employment > ERISA litigation
- Finance > Fintech
- Healthcare > Life sciences
- Dispute resolution > M&A litigation: defense
- Intellectual property > Patents: litigation (full coverage)
- Real estate > Real estate
- Dispute resolution > Securities litigation: defense
- Intellectual property > Trade secrets (litigation and non-contentious matters)
- M&A/corporate and commercial > Shareholder activism
- Dispute resolution > Appellate: courts of appeals / Appellate: supreme courts (states and federal)
- Finance > Capital markets: debt offerings
- International trade and national security > CFIUS
- Finance > Commercial lending
- M&A/corporate and commercial > Corporate governance
- Labor and employment > Employee benefits, executive compensation and retirement plans: transactional
- Dispute resolution > Financial services litigation
- Antitrust > Merger control
- Investment fund formation and management > Private equity funds (including venture capital)
- Dispute resolution > Product liability, mass tort and class action - defense: consumer products (including tobacco)
- Tax > US taxes: non-contentious
- Labor and employment > Workplace and employment counseling
- International trade and national security > Customs, export controls and economic sanctions
- Media, technology and telecoms > Cyber law (including data privacy and data protection)
- Intellectual property > Patents: litigation (International Trade Commission)
- Intellectual property > Patents: prosecution (including re-examination and post-grant proceedings)
- Healthcare > Service providers
- Antitrust > Civil litigation/class actions: defense
- Dispute resolution > Leading trial lawyers
- Dispute resolution > Leading trial lawyers
- M&A/corporate and commercial > M&A: large deals ($1bn+)
- Real estate > Real estate finance
- Finance > Restructuring (including bankruptcy): corporate
- Dispute resolution > Corporate investigations and white-collar criminal defense
- Finance > Financial services regulation